Author/Editor     Vene, Nina
Title     Antikoagulacijsko zdravljenje pri bolnikih z atrijsko fibrilacijo
Translated title     Anticoagulant treatment in atrial fibrillation
Type     članek
Source     In: Urlep-Šalinović V, editor. Hemostatske motnje. Strokovno srečanje ob 30-letnici hemostaziološke dejavnosti v Splošni bolnišnici Maribor; 2006 maj 26; Maribor. Maribor: Splošna bolnišnica Maribor,
Publication year     2006
Volume     str. 177-88
Language     slo
Abstract     Atrial fibrillation (AF) is a major independent risk factor for stroke. The overall risk of stroke in nonvalvular AF patients averages about 5%/y, but with wide variation depending on the presence of coexistent risk factors. Advancing age, prior stroke or transient cerebral ischaemia, hypertension, impaired left ventricular systolic function and/or congestive heaert failure and diabetes mellitus are known risk factors. Stratification of stroke risk identifies nonvalvular AF patients who benefit most and least from anticoagulation. Oral anticoagulation with warfarin (target range INR 2, 0-3,0) reduces the stroke risk by two-thirds and is recommended for AF patients with additional risk factors. Patients with paroxysmal AF are treated in a manner similar to chronic AF, anticoagulation is based on the presence of risk factors. Cardioversion of AF does not reduce the stroke risk. For patients with atrial fibrillation lasting more than 48 hours anticoagulation 3 weeks prior and at least 4 weeks post-cardioversion is indicated. For patients with AF of known duration of less than 48 hours anticoagulation with heparin or low mlecualr heparin is recommended. Longterm continuation of anticoagulation after cardioversion is based on number of AF episodes and the risk factor status.
Descriptors     ATRIAL FIBRILLATION
ANTICOAGULANTS
CEREBRAL INFARCTION